Trial · NCT01834729

Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions

NCT01834729, Phase 2, Completed, Mayo Clinic; results first posted 2019-01-11

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions. Trials, record NCT01834729. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01834729

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions
NCT number: NCT01834729
Status: Completed
Phases: Phase 2
Enrollment: 74 participants, actual
Lead sponsor: Mayo Clinic
Conditions: Constipation
Interventions: Alfuzosin, Placebo
First posted: 2013-04-18
Last updated: 2019-01-29
Results first posted: 2019-01-11
Limitations and caveats: Men were not studied; baseline bowel diary was not preceded by a run-in period; treatment phase only lasted 2 weeks.

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Weekly Rate of Spontaneous Bowel Movements at 4 Weeks	4 weeks	A bowel movement is considered a spontaneous bowel movement (SBM) if no laxative, enema, or suppository was taken in the preceding 24 hours.
Primary	Weekly Rate of Complete Spontaneous Bowel Movements at 4 Weeks	4 weeks	If the subject indicates that the spontaneous bowel movement (SBM) was associated with a sensation of complete bowel emptying, the SBM will be counted as a complete spontaneous bowel movement (CSBM).

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Weekly Rate of Spontaneous Bowel Movements at 4 Weeks	4 weeks		spontaneous bowel movements per week	MEAN
PRIMARY	Weekly Rate of Complete Spontaneous Bowel Movements at 4 Weeks	4 weeks		complete SBM per week	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Weekly Rate of Spontaneous Bowel Movements at 4 Weeks	Control Placebo	1.6	Standard Error 0.3	spontaneous bowel movements per week
Weekly Rate of Spontaneous Bowel Movements at 4 Weeks	Control Alfuzosin	1.3	Standard Error 0.1	spontaneous bowel movements per week
Weekly Rate of Spontaneous Bowel Movements at 4 Weeks	Constipation Placebo	1.6	Standard Error 0.4	spontaneous bowel movements per week
Weekly Rate of Spontaneous Bowel Movements at 4 Weeks	Constipation Alfuzosin	1.3	Standard Error 0.1	spontaneous bowel movements per week
Weekly Rate of Complete Spontaneous Bowel Movements at 4 Weeks	Control Placebo	0.6	Standard Error 0.1	complete SBM per week
Weekly Rate of Complete Spontaneous Bowel Movements at 4 Weeks	Control Alfuzosin	0.7	Standard Error 0.05	complete SBM per week
Weekly Rate of Complete Spontaneous Bowel Movements at 4 Weeks	Constipation Placebo	0.7	Standard Error 0.1	complete SBM per week
Weekly Rate of Complete Spontaneous Bowel Movements at 4 Weeks	Constipation Alfuzosin	0.7	Standard Error 0.1	complete SBM per week

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Control Placebo	18
Overall Study	STARTED	Control Alfuzosin	20
Overall Study	STARTED	Constipation Placebo	18
Overall Study	STARTED	Constipation Alfuzosin	18
Overall Study	COMPLETED	Control Placebo	17
Overall Study	COMPLETED	Control Alfuzosin	19
Overall Study	COMPLETED	Constipation Placebo	15
Overall Study	COMPLETED	Constipation Alfuzosin	16
Overall Study	NOT COMPLETED	Control Placebo	1
Overall Study	NOT COMPLETED	Control Alfuzosin	1

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Hypotension	Cardiac disorders	Control Placebo	0	18	0
other	Hypotension	Cardiac disorders	Control Alfuzosin	1	20	1
other	Hypotension	Cardiac disorders	Constipation Placebo	0	18	0
other	Hypotension	Cardiac disorders	Constipation Afluzosin	0	18	0
other	Headache	General disorders	Control Placebo	0	18	0
other	Headache	General disorders	Control Alfuzosin	0	20	0
other	Headache	General disorders	Constipation Placebo	0	18	0
other	Headache	General disorders	Constipation Afluzosin	1	18	1
other	Fatigue	General disorders	Control Placebo	0	18	0
other	Fatigue	General disorders	Control Alfuzosin	0	20	0

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Control Placebo	0	18
Total, all-cause mortality	Control Alfuzosin	0	20
Total, all-cause mortality	Constipation Placebo	0	18
Total, all-cause mortality	Constipation Afluzosin	0	18
Total, other adverse events	Control Placebo	0	18
Total, other adverse events	Control Alfuzosin	1	20
Total, other adverse events	Constipation Placebo	1	18
Total, other adverse events	Constipation Afluzosin	1	18
Total, serious adverse events	Control Placebo	0	18
Total, serious adverse events	Control Alfuzosin	0	20

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
30130627	RESULT

Source PubMed

Grants2

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
R01DK078924	Pathophysiology of Anorectal Disorders	BHARUCHA, ADIL E.	MAYO CLINIC ROCHESTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES	2008 to 2023	NIH RePORTER
UL1RR024150	Mayo Clinic Center for Translational Science Activities	RIZZA, ROBERT A.	MAYO CLINIC ROCHESTER	NATIONAL CENTER FOR RESEARCH RESOURCES	2006 to 2011	NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01834729

GET https://conductscience.org/api/trials/v1/NCT01834729/registered

API reference For AI assistants